

FACT SHEET

RECCE PHARMACEUTICALS LTD (ASX:RCE, FSE:R9Q)

FEBRUARY 2026



An Emerging Global Leader in a New Generation of Anti-Infectives

Recce Pharmaceuticals Ltd (ASX:RCE, FSE:R9Q) is an Australian clinical stage biotech company engaged in the development and commercialisation of **a new class of Synthetic Anti-infectives designed to address the urgent global health problem of antimicrobial resistant (AMR) superbugs.**

Recce's lead candidate, RECCE® 327 (R327), is a patented, **broad-spectrum synthetic anti-infective being developed in multiple formulations, including intravenous and topical.** It is designed to treat serious bacterial infections, including those caused by drug-resistant **Gram-positive** and **Gram-negative** pathogens.

R327 as a Topical Gel (R327G) is currently advancing through **late-stage clinical development**, with a particular focus on addressing **diabetic foot infections (DFIs)**, a major complication of diabetes and a significant global health burden. Recce is also advancing a broader portfolio of synthetic anti-infectives targeting a range of unmet medical needs across bacterial and viral infections.

The Company's lead program is a Registrational Phase 3 trial of R327G for DFIs in Indonesia, with patient dosing now underway at five sites. The trial is designed to generate pivotal safety and efficacy data and serves as a potential gateway to broader regulatory and commercial opportunities across the ASEAN market.

The Company also has a Cooperative Research and Development Agreement signed with US Army Medical Research Institute of Infectious Diseases, to test R327 against biothreat pathogens in established *in vitro* models targeting burn wound infections.

Recce's **fully owned, automated manufacturing facility** in Australia supports ongoing clinical development and scale-up. With a **strong global patent portfolio** and a **targeted focus on unmet medical needs in diabetic wound care**, **Recce is advancing a next-generation anti-infective platform poised for near-term commercialisation and global expansion.**

Corporate Summary

- Proprietary New Class of Anti-Infectives against bacteria and viruses, protected by Composition of Matter Patent.
- **World's Most Clinically Advanced New Class of Anti-Infectives focussed upon the urgent global health threat of antibiotic-resistant superbugs.**
- Multiple Clinical Trials Complete, others underway - **Broad spectrum therapeutic potential for major unmet medical needs of Sepsis/Urosepsis, Burn Wound Infections, ABSSSIs, Diabetic Foot Infections and more**
- R327 bactericidal activity against all ESKAPEE pathogens.
- R327 cleared for use under **Therapeutic Goods Administration (TGA) Special Access Scheme (SAS) - Category A**
- **Global recognition by the World Health Organization - inclusion underscores significance of R327 in combating AMR. R327 uniquely classified as an adenosine triphosphate (ATP) production disruptor**, the only compound under this category **development for priority pathogens**, recognising Recce's efforts to combat antimicrobial resistance.
- **R327 has been awarded Qualified Infectious Disease Product (QIDP) designation by the U.S. FDA under the GAIN Act, providing Fast Track status and 10 years of market exclusivity post-approval.**
- Australian Government awarded **AUD \$54,947,284 (USD \$37,043,433) Advanced Overseas Finding*** across RCE infectious disease portfolio*

SNAPSHOT

Ticker	ASX:RCE, FSE:R9Q
Date listed	January 2016, March 2021
52 week range	AUD \$0.2750 - A\$0.7300
Market Cap	AUD \$179.40m (priced at \$0.6100)
Shares on issue	289.18m
3 month avg. vol	139.78K (per trading day)
Sector	Pharmaceuticals, Biotechnology & Life Sciences

BOARD AND MANAGEMENT

Dr John Prendergast	Executive Chairman
James Graham	Managing Director & Chief Executive Officer
Michele Dilizia	Executive Director & Chief Scientific Officer
Dr Justin Ward	Executive Director & Principal Quality Chemist
Dr Alan W Dunton	Chief Medical Advisor & Non-Executive Director
Alistair McKeough	Non-Executive Director
Arthur Kollaras	Head of Manufacturing
Justin Reynolds	CFO (Outsourced - Pitcher Partners Sydney)
Maggie Niewidok	Company Secretary (Outsourced - Kardos Scanlan)

PATENT PORTFOLIO

Patents covering the manufacturing process run until 2029. Granted provisional patents covering additional modes of delivery and anti-viral uses, run until 2037.

Recce Pharmaceuticals Ltd patent portfolio has continued to strengthen with granted patents in key pharmaceutical markets such as USA, Europe, Japan, China and Australia.

FILED	PATENT FAMILY 1	EXPIRY	PATENT FAMILY 2	EXPIRY	PATENT FAMILY 3	EXPIRY
Australia	✓	2028	✓	2037	✓	2037
USA	✓	2029	✓	2037	✓	2037
Europe	✓	2028	✓	2037	✓	2037
Germany	✓	2028	✓	2037	✓	2037
Spain	✓	2028	✓	2037	✓	2037
France	✓	2029	✓	2037	✓	2037
UK	✓	2028	✓	2037	✓	2037
Italy	✓	2028	✓	2037	✓	2037
Sweden	✓	2028	✓	2037	✓	2037
Japan	✓	2028	✓	2037	✓	2037
China	✓	2028	✓	2037	✓	2037
HK	Pending	2028	Pending	2037	✓	2037

Patent Family 1 - **Granted**

Unique and highly economical manufacturing process

Patent Family 2 - **Pending/Granted**

Applications (Multi-drug delivery)

Patent Family 3 - **Granted**

Anti-viral use


Patent Family 4 - **Pending/Granted**

Process for Preparation of Biologically Active Copolymer


Australia, Israel, Canada, Japan, China and Hong Kong - Granted

Other Patent Cooperation Treaty - **pending/allowed**

RECCE® 327 Mechanism of Action



RECCE® Multiple Anti-Infective Applications



Efficacy - RECCE® 327

- Achieved a 93% positive clinical response in diabetic foot infection (DFI) patients during Phase II trials, with **no serious adverse events reported**
- Multiple SAS Category A patient cases in Australia have shown **rapid clinical improvement with RECCE® 327 Topical Gel**, including the avoidance of surgical intervention in severe infections
- In SAS Category A use, R327 demonstrated visible reductions in swelling, redness, and infection progression within 24–72 hours of a single application
- **Maintains potency across both Gram-positive and Gram-negative bacteria, including their drug-resistant variants**
- Time-kill studies show RECCE® 327 acts faster than conventional antibiotics, rapidly depleting bacterial ATP and causing irreversible bacterial death
- **Demonstrated 99.9% *in vitro* efficacy against the full suite of ESKAPEE pathogens**

Safety - RECCE® 327

- **R327 has been shown to be safe and well tolerated across multiple Phase I and II clinical trials and/or SAS Category A patient cases – as either intravenous or topical gel**
- Phase I trials demonstrated intravenous **safety profile even at high doses up to 6,000 mg** delivered over a one-hour infusion
- No clinically significant changes were observed in laboratory tests, EKGs, telemetry, or vital signs, supporting systemic safety
- R327 displayed a clear therapeutic window across multiple dosing schedules and concentrations
- **Topical application has shown to be non-irritating and well tolerated, even in infected, open wound sites**
- **Multiple R327 studies of mutagenicity (cancer) are clear**



Sydney – Head Office

Level 15, 1 Farrer Place
Governor Macquarie Tower
Sydney NSW 2000
Australia

Macquarie Park – Production

Unit 8, 64 Talvera Road
Macquarie Park NSW 2113
Australia

Perth – R&D Centre

Suite 10, 3 Brodie Hall Drive
Technology Park
Bentley WA 6102
Australia

North America – Operations

Suite 1025
1717 Pennsylvania Avenue
Washington DC 20006
USA

Recce Pharmaceuticals Ltd makes no warranties or representations regarding the accuracy or completeness of the information contained in this investor fact sheet. Certain statements made may contain forward looking statements, which involve known and unknown risk, uncertainties and other factors, which may cause the actual results or performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward looking statements.